Diagnostic assistance, quantification, characterization, image reconstruction: medical artificial intelligence at your fingertips for radiology.
Back to AI solutions

Transpara

AI for early breast cancer detection and enhanced reading workflow.

Discover

Transpara assists radiologists in their interpretation of a mammography exam. Transpara provides a probability of the presence of breast cancer based on automatically detected and AI-scored lesions. Transpara detection works on 2D and tomosynthesis.

Breast cancer is the most commonly diagnosed cancer in women, and accounts for 1 in 4 annual cancer cases worldwide. The European guidelines recommend screening in all women aged 45 to 74 years between every 2-3 years. Breast cancer screening is challenging, even to the expert eye, and the balance of not missing any cancers, while not calling too many False Positives is crucial.
Transpara CE

Transpara Detection

Transpara Detection is the cornerstone of the Transpara® Breast AI Suite. Its best-in-class AI detects cancers earlier and stratifies studies by risk, enabling a clear and consistent workflow. It performs automatic segmentation and contouring of suspicious regions, evaluates malignancy levels for each detected lesion, and assigns regional scores for microcalcifications and suspicious tissue areas.


Transpara Temporal Comparison

Transpara Temporal Comparison automatically compares each mammogram with up to three prior exams from as far back as 6.5 years. By refining the analysis from Transpara Detection, it enhances both sensitivity and specificity - giving you greater confidence through a more accurate assessment.


Transpara Density

Transpara’s Density automates breast density assessment for both 3D and 2D mammograms. Compatible, consistent, and clear, Transpara Density brings algorithms for both volumetric breast density and BI-RADS-like composition into your existing workflow.


Increase cancer detection with Transpara as your second pair of eyes.

Reduce workload and reading time by focusing your attention where it matters most.

Identify and qualify benign or malignant lesions faster and with higher accuracy, improving detection of subtle cancers and reducing false negatives.

Save time, secure your diagnosis and optimize your workflow with Incepto

Request a demo

Publications

  1. Tiffany T Yu, Anne C Hoyt, Melissa M Joines, Cheryce P Fischer, Nazanin Yaghmai, James S Chalfant, Lucy Chow, Shabnam Mortazavi, Christopher D Sears, James Sayre, Joann G Elmore, William Hsu, Hannah S Milch (2025). Mammographic classification of interval breast cancers and artificial intelligence performance. JNCI: Journal of the National Cancer Institute

  2. V Hernström, V Josefsson, H Sartor, D Schmidt, A-M Larsson, S Hofvind, I Andersson, A Rosso, O Hagberg, K Lång (2025). Screening performance and characteristics of breast
    cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study. Lancet Digital Health.

  3. E Elías‐Cabot, S Romero‐Martín, JL Raya‐Povedano, A‐K Brehl and M Álvarez‐Benito (2023) Impact of real‐life use of artificial intelligence as support for human reading in a population‐based breast cancer screening program with mammography and tomosynthesis. Eur Radiology.

  4. M Larsen, CF Aglen, C Lee, SR Hoff, H Lund-Hanssen, K Lång, J Nygård, G Ursin, S Hofvind. (2022). Artificial Intelligence Evaluation of 122 969 Mammography Examinations from a Population-based Screening Program. Radiology.

  5. SL van Winkel, A Rodríguez-Ruiz, L Appelman, A Gubern-Mérida, N Karssemeijer, J Teuwen, AJT Wanders, I Sechopoulos, RM Mann (2021). Impact of artificial intelligence support on accuracy and reading time in breast tomosynthesis image interpretation: a multi-reader multi-case study. Eur Radiology.

Regulatory

Transpara medical device is a regulated health product that bears the CE mark, Class IIb. Notified Body: DEKRA Certification B.V. n°0344. Manufacturer: ScreenPoint Medical B.V. Transpara is a diagnostic tool and shall not be used alone to recommend medical care for diagnostic purposes. Please read the instructions in the user manual carefully. Please contact [email protected] for more information. Last update: 2026/10/28

Contact us to know if this product is available in your country.

Publisher

ScreenPoint Medical is a Dutch company founded in 2014 by Professors Nico Karssemeijer and Mike Brady. Pioneers in their field, they assembled a team of experts in breast imaging and artificial intelligence to develop a decision support algorithm. The team’s ultimate goal is to facilitate early detection of breast cancer, improving survival rates and enabling earlier treatment with less invasive methods.